Results 151 to 160 of about 35,802 (259)
The Enigma of Finnish and Sardinian Type 1 Diabetes Incidence: Where Population History Meets Genetics. [PDF]
Bougnères P.
europepmc +1 more source
Polygenic risk scores in human genetics for study design discovery and translation. [PDF]
Qu HQ, Hakonarson H.
europepmc +1 more source
Abstract Racial inequalities are pervasive in higher education despite concerted efforts to redress issues of access, progression and continuation. Little attention has been paid to how universities themselves construct race within their policy texts.
Benjamin Hart, Mirna Šumatić
wiley +1 more source
Risk and liability in the deployment of AI systems for surgery: a SAGES white paper. [PDF]
Hashimoto DA +4 more
europepmc +1 more source
Abstract Debates surrounding motherhood have long centred on women's roles as carers. Although motherhood is now more widely recognised within feminist scholarship, it often remains conceptually separate from identities associated with formal educational discourse.
Lavinia Kamphausen +3 more
wiley +1 more source
Research on intellectual property rights and legal liability definition of artificial intelligence-assisted pediatric disease diagnosis system. [PDF]
Yang Z, Yang W.
europepmc +1 more source
Publishing the History of Radical Science in a Time of Digital Capitalism
This paper investigates publishing as a practice in the history of science. It firstly provides an experiential account of building a DIY‐inspired publishing venue for collective, source‐based narration. The venue used the possibilities of digital publishing to apply, rather than simply refer to, a very striking aspect of radical science in the 1970s ...
Niki Rhyner
wiley +1 more source
Causal effects of cholelithiasis on hepatopancreatobiliary diseases: a multi-cohort Mendelian randomization study. [PDF]
An J +8 more
europepmc +1 more source
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga +2 more
wiley +1 more source

